# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Evercore ISI Group analyst Vijay Kumar maintains Boston Scientific (NYSE:BSX) with a Outperform and raises the price target ...
- SEC Filing
Needham analyst Mike Matson reiterates Boston Scientific (NYSE:BSX) with a Buy and maintains $82 price target.
Boston Scientific to acquire Silk Road Medical for $1.26 billion, enhancing its vascular portfolio with Silk Road's TCAR sy...
Boston Scientific expects to complete the transaction in the second half of 2024, subject to customary closing conditions. Sil...